Plain-English translation of NCT06991114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment called AlloNK® — immune cells collected from donated umbilical cord blood — paired with rituximab, an antibody therapy you may already know about. The goal is to see if this combination can help people whose autoimmune diseases (like rheumatoid arthritis, scleroderma, or muscle inflammation) have not improved with standard treatments. Researchers will watch carefully to make sure the treatment is safe and to measure whether it actually reduces your symptoms.
Many people with serious autoimmune diseases don't respond well enough to current medications, leaving them in pain or with worsening symptoms. This trial exists to test whether adding specially prepared immune cells might help these stubborn cases — essentially giving the body's immune system a better chance to calm down the disease.
You likely qualify if…
You likely don't qualify if…
You would receive a conditioning regimen (a short course of medication to prepare your body) followed by an infusion of the immune cells, combined with rituximab. The exact schedule of visits and duration would depend on your disease type and the study protocol. You would be closely monitored over weeks and months with blood tests, symptom assessments, and imaging to track whether the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States